The fifth and final patient in the phase 1/2a clinical trial of TT-034, a
ddRNAi-based therapeutic to treat hepatitis C virus infection, has been
dosed, according to a news release from Benitec Biopharma Limited.
The phase 1/2 clinical trial being conducted
at the Duke Clinical Research Unit of Duke Clinical Research Institute
is an open-label dose escalation study that evaluates the safety and
activity of single doses of TT-034 (Benitec), a potential treatment for
HCV with a single-dose administration, in patients with chronic HCV
genotype 1 infection who have failed previous treatments, according to
the Duke Clinical Research Unit website. The trial consists of 14
patients in five sequential dose cohorts.
Patients in cohort two received an increased dose of TT-034
that was a half-log higher than patients dosed in the first cohort,
according to the release. The dose level was still below the
concentration expected to inhibit HCV viral replication, according to the release.
Labels: ", "one-shot, Benitec, clinical trial, TT-034